Medtronic (MDT) Asset Writedowns and Impairment (2014 - 2026)

Medtronic has disclosed Asset Writedowns and Impairment across 13 years of filings, most recently posting $36.0 million for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $36.0 million, down 29.41% year-over-year; the trailing twelve-month figure through Jan 2026 was $129.0 million (down 68.15% YoY), and the FY2025 annual result was $123.0 million, down 66.85% from the prior year.
• Asset Writedowns and Impairment came in at $36.0 million for Q1 2026 at Medtronic, down from $38.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $466.0 million in Q2 2022 to a low of -$466.0 million in Q1 2022.
• The 5-year median for Asset Writedowns and Impairment is $26.0 million (2022), against an average of $39.4 million.
• Peak annual rise in Asset Writedowns and Impairment reached 1764.0% in 2022, while the deepest fall reached 552.43% in 2022.
• Medtronic's Asset Writedowns and Impairment stood at $26.0 million in 2022, then slumped by 38.46% to $16.0 million in 2023, then surged by 68.75% to $27.0 million in 2024, then surged by 40.74% to $38.0 million in 2025, then fell by 5.26% to $36.0 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $36.0 million (Q1 2026), $38.0 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.